Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

Atlassian Corp Plc (NASDAQ:TEAM) reported its fourth-quarter 2024 earnings, significantly surpassing market expectations with an EPS of $0.96 against a forecast of $0.62. The company also exceeded ...